J Korean Med Assoc.  2011 Oct;54(10):1020-1027.

Evidence-based management and treatment of high-risk individuals with pre-diabetes

• Chun KH

Abstract

The prevalence of type 2 diabetes (T2DM) has increased dramatically during the last decade, especially in Asian population. The control of hyperglycemia is very important for diabetes patients. Prevention of T2DM should be a major public health goal because of its substantial effect on heath. Treatment of high-risk individuals with impaired fasting glucose and impaired glucose tolerance to prevent T2DM has important medical, economic, social, and human implications. Identifying risk factors affecting transition diabetes is thus very important. Having defined a patient population at high-risk for developing diabetes, the intensive intervention of diet, physical activity, lifestyle modification, and drug therapy (metformin) can substantially affect the delay and prevention of T2DM. Tight glucose control has the potential to reduce the incidence and prevalence of T2DM.

Keyword

Impaired fasting glucose; Impaired glucose tolerance; Prediabetes state; Evidence-based intervention

MeSH Terms

Asian Continental Ancestry Group
Diet
Fasting
Glucose
Humans
Hyperglycemia
Incidence
Life Style
Motor Activity
Prevalence
Public Health
Risk Factors
Glucose

Reference

References

1. Statistics Korea. Annual report on the cause of death statistics 2010 [Internet]. Deajeon: Statistics Korea;2011. [cited 2011 Sep 19]. Available from:. http://kostat.go.kr.

2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007 [Internet]. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention;2008. [cited 2011 Sep 19]. Available from:. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.

3. International Diabetes Federation. Diabetes atlas. 4th ed.Brussels: International Diabetes Federation;2009.

4. The Ministry of Health and Welfare; Korea Centers for Disease Control and Prevention. Korea health statistics 2009: Korea National Health and Nutrition Examination Survey (KNHANESIV-3). Seoul: Korea Centers for Disease Control and Prevention;2010.

5. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. Alberti K, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabets mellitus. London: John Wiley & Sons;1997. p. 3–18.

6. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H. HbA1c 5.7–6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011; 378:147–155.

7. Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDI TION study, Denmark. Diabetologia. 2008; 51:249–257.

8. Alberti KG. Impaired glucose tolerance: fact or fiction. Diabet Med. 1996; 13(3 Suppl 2):S6–S8.

9. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997; 46:701–710.

10. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753–759.

11. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999; 22:623–634.

12. The Diabetes Prevention Program. baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care. 2000; 23:1619–1629.

13. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. Diabetes Prevention Program Research Group. The diabetes prevention program and its global implications. J Am Soc Nephrol. 2003; 14(7 Suppl 2):S103–S107.

14. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996; 19:1190–1193.

15. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980; 1:1373–1376.

16. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care. 1989; 12:464–474.

17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539–553.

18. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999; 42:793–801.

19. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343–1350.

20. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20:537–544.

21. Koplan JP, Dietz WH. Caloric imbalance and public health policy. JAMA. 1999; 282:1579–1581.

22. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med. 1999; 16:2–13.

23. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405–412.

24. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997; 46:1354–1359.

25. Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year followup from the time of diagnosis. Diabetes Care. 1998; 21:1861–1869.

26. Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J. 1999; 138(5 Pt 1):S353–S359.

27. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulindependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994; 25:1157–1164.

28. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulindependent diabetes. Stroke. 1996; 27:63–68.

29. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other protentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002; 25:894–899.

30. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care. 1996; 19:607–612.

31. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995; 18:258–268.

32. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2):90–96.

33. Lee ET, Lee VS, Lu M, Lee JS, Russell D, Yeh J. Incidence of renal failure in NIDDM. The Oklahoma Indian Diabetes Study. Diabetes. 1994; 43:572–579.

34. Yokoyama H, Okudaira M, Otani T, Watanabe C, Takaike H, Miuira J, Yamada H, Mutou K, Satou A, Uchigata Y, Iwamoto Y. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care. 1998; 21:1080–1085.

35. Lee JH. Diabetic cardiac autonomic neuropathy: Symptoms, diagnosis and treatment. Korean Clinical Diabetes J. 2010; 11:195–198.

36. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23(Suppl 2):B21–B29.

37. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000; 48:201–210.

38. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837–853.

39. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:854–865.

40. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999; 22:1125–1136.

41. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care. 2011; 34(Suppl 1):S11–S61.

42. Korean Diabetes Association. Diabetes. Seoul: Korea Medicine;2005.

43. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33:1578–1584.

44. Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF. AusDiab Study Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2010; 33:757–762.

45. Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Yamashita H, Ito H, Yoshimura Y, Ohashi Y, Akanuma Y, Yamada N. Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53:419–428.

46. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002; 25:512–516.

47. Korea Centers for Disease Control and Prevention. Results of the secondary follow-up survey of the Anseong and Ansan cohorts. Seoul: Center for Genome Science;2008.

48. Korea National Diabetes Program. KNDP participation organ [Internet]. Seoul: Korea Healthcare Technology R&D Project, Ministry of Health and Welfare;2006. [cited 2011 Oct 4]. Available from:. http://www.kndp.or.kr/project/sub2_4.html.